FGF9 and cancer: Our group has recently shown that in EG cancer models, the overexpression of FGFR3 and Fibroblast Growth Factor 9 (FGF9) sustains acquired resistance to trastuzumab, through the activation of PI3K/AKT/Mammalian target of the rapamycin (mTOR) signaling pathway.